Extavia

Approved Uses

Extavia is used to manage various relapsing forms of multiple sclerosis (MS). The primary goals of treatment are to decrease the frequency of clinical exacerbations (also known as relapses or flares) and to slow the accumulation of physical disability caused by the disease. It is specifically indicated for:

• Clinically Isolated Syndrome (CIS): This is used for patients who have experienced a first clinical episode of neurologic symptoms and have magnetic resonance imaging (MRI) features consistent with MS.
• Relapsing-Remitting MS (RRMS): This is the most common form of MS, characterized by clearly defined attacks of worsening neurologic function followed by periods of partial or complete recovery.
• Active Secondary Progressive MS (SPMS): This is a stage of MS that follows an initial relapsing-remitting course, where the disease continues to progress and includes active relapses.

Extavia belongs to a class of medications called interferons. While it helps manage the symptoms and progression of the disease, it is not a cure for multiple sclerosis.

How Extavia Works

Extavia is a medication known as an interferon beta-1b. Interferons are proteins that the body produces naturally to help the immune system respond to viruses and regulate inflammation. In people with multiple sclerosis (MS), the immune system mistakenly attacks the protective coating of the nerves in the brain and spinal cord.

While the precise mechanism of how Extavia works in MS is not fully understood, it is believed to help manage the condition through several actions on the immune system:

• Reducing Inflammation: It helps balance the production of pro-inflammatory and anti-inflammatory substances in the body, which can reduce the swelling and damage to nerve fibers.
• Limiting Immune Cell Movement: It may help prevent certain white blood cells from crossing the blood-brain barrier. This keeps these cells from entering the central nervous system where they could cause damage.
• Modifying Immune Response: It alters the way immune cells interact with each other, making them less likely to trigger an attack on the body's own tissues.

By modulating these immune activities, Extavia helps to reduce the frequency of MS relapses (flares) and may help slow the progression of physical disability associated with the disease.

Common Side Effects

The most frequent side effects of Extavia are flu-like symptoms and reactions at the site of injection. Flu-like symptoms often improve as the body adjusts to the medication and may include:

• Fever and chills
• Muscle aches
• Sweating
• Tiredness or weakness

Injection site reactions are common and typically involve redness, pain, or swelling. Other common side effects include headache, stomach pain, and sleep disturbances.

Serious Side Effects

Some side effects can be serious and may require medical intervention. Contact a healthcare provider if you experience:

• Mental health changes: New or worsening depression, anxiety, or suicidal thoughts.
• Liver injury: Yellowing of the skin or eyes, dark urine, or pain in the upper right stomach area.
• Severe skin reactions: Skin breakdown or tissue death (necrosis) at the injection site.
• Heart problems: Swelling in the legs or ankles, or sudden shortness of breath.
• Blood cell changes: Signs of low blood counts, such as unusual bruising, bleeding, or frequent infections.
• Seizures: New or more frequent seizures.
• Allergic reactions: Difficulty breathing, hives, or swelling of the face and throat.

Liver Injury

Extavia has been associated with serious liver injury, including rare instances of liver failure. Healthcare providers usually perform liver function tests before treatment begins and periodically thereafter to monitor for signs of damage.

Depression and Suicide

There is an increased risk of depression and suicidal ideation among patients using interferon beta products. Close monitoring for new or worsening symptoms of depression, anxiety, or changes in behavior is recommended.

Injection Site Reactions

Severe reactions at the site of injection, including tissue death (necrosis), can occur. It is important to use proper injection techniques and rotate the areas where the medication is administered to minimize damage.

Blood Disorders

Treatment may lead to a decrease in blood cell counts, such as white blood cells (leukopenia) and platelets (thrombocytopenia). Additionally, rare cases of thrombotic microangiopathy (TMA), a condition involving blood clots in small vessels, have been reported.

Heart and Seizure Risks

• Heart Failure: Patients with pre-existing congestive heart failure should be monitored for worsening symptoms.
• Seizures: Seizures have occurred in patients taking this medication, including those without a previous history of seizures.

Allergic Reactions

Serious allergic reactions, including anaphylaxis, are possible. Extavia should not be used by individuals with a known hypersensitivity to natural or recombinant interferon beta, albumin, or any other ingredient in the formulation.

Pregnancy

The effects of Extavia on human pregnancy are not fully known, as there are no adequate and well-controlled studies in pregnant women. However, animal studies have indicated that interferon beta-1b may increase the risk of spontaneous abortion (miscarriage). Due to these findings, healthcare providers generally recommend using this medication during pregnancy only if the potential benefits outweigh the potential risks to the developing fetus.

If you are pregnant or planning to become pregnant, it is important to discuss your treatment plan with your healthcare provider. If you become pregnant while using Extavia, you should notify your doctor immediately to evaluate the risks and benefits of continuing the medication.

Breastfeeding

It is not known whether Extavia passes into human breast milk. Because many drugs are excreted in human milk and there is a potential for serious adverse reactions in nursing infants, a decision must be made whether to discontinue nursing or discontinue the drug. This decision should take into account the importance of the medication to the mother's health and should be discussed thoroughly with a healthcare professional.

Dosage Forms

Extavia is supplied as a sterile, lyophilized powder in a single-dose vial. It is intended for subcutaneous injection after being reconstituted with the provided diluent.

Packaging

The medication is typically provided in a kit containing the components necessary for administration. These kits usually include:

• A vial of the medication powder.
• A pre-filled syringe containing the diluent (sodium chloride solution).
• A vial adapter with an attached needle.
• Alcohol swabs.

The powder should appear as a white to off-white cake. Once mixed, the solution should be clear and colorless to light yellow. Each vial is for a single use only, and any unused portion of the solution should be discarded.

FDA Approval and Indications

Extavia was approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsing forms of multiple sclerosis. The approved indications include:

• Clinically isolated syndrome (a single first episode of MS symptoms)
• Relapsing-remitting disease
• Active secondary progressive disease

Safety Monitoring and Communications

The FDA monitors the safety of medications after they reach the market. In 2016, the FDA identified a potential signal of a serious risk for thrombotic microangiopathy (TMA) associated with interferon beta products, including Extavia. TMA is a rare condition that causes blood clots to form in small blood vessels throughout the body.

Regulatory Warnings

While Extavia does not have a boxed warning, the FDA-approved labeling includes several significant warnings and precautions for patients and healthcare providers:

• Liver Injury: There is a risk of severe hepatic injury, and liver function tests are required during treatment.
• Depression and Suicide: Patients should be monitored for depression, suicidal thoughts, or other emotional changes.
• Injection Site Reactions: Severe reactions, including necrosis (skin and tissue death), can occur at the injection site.
• Anaphylaxis: Serious allergic reactions have been reported.
• Congestive Heart Failure: Patients with pre-existing heart conditions should be monitored for worsening symptoms.
• Blood Cell Counts: The medication may cause a decrease in white blood cell and platelet counts.

Insurance Coverage

Extavia is a specialty medication, and its cost is largely determined by your health insurance plan. It is often placed on a higher tier of the drug formulary, which may require you to pay a percentage of the drug's cost (coinsurance) rather than a fixed copayment. Most insurance plans also require prior authorization, meaning your doctor must get approval from the insurer before the medication will be covered.

Specialty Pharmacy Distribution

Because Extavia requires specific handling and patient support, it is typically dispensed through specialty pharmacies rather than standard retail pharmacies. These pharmacies coordinate with your insurance and may offer delivery services for the medication.

Financial Assistance

For patients who have difficulty affording their medication, financial assistance programs may be available. These can include manufacturer-sponsored programs or support from non-profit organizations that help cover out-of-pocket costs for individuals with multiple sclerosis who meet certain eligibility requirements.